Renal and Hormonal Effects of Pioglitazone

PHASE4CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

October 31, 2007

Study Completion Date

October 31, 2007

Conditions
DiabetesHypertension
Interventions
DRUG

Pioglitazone

placebo-controlled, randomized, cross-over study was to explore the effects of pioglitazone (45 mg q.d. for 6 weeks) on the renal, hormonal and blood pressure responses to changes in sodium intake in a population prone to insulin resistance

DRUG

Metformin

placebo-controlled, randomized, cross-over study was to explore the effects of pioglitazone (45 mg q.d. for 6 weeks) on the renal, hormonal and blood pressure responses to changes in sodium intake in a population prone to insulin resistance

Trial Locations (1)

1211

Pechère-Bertschi Antoinette, Geneva

All Listed Sponsors
collaborator

University of Lausanne Hospitals

OTHER

lead

University Hospital, Geneva

OTHER

NCT01090752 - Renal and Hormonal Effects of Pioglitazone | Biotech Hunter | Biotech Hunter